 Co-Diagnostics Inc has strengthened its intellectual property portfolio after being awarded a patent in the Republic of Korea for the companys CoPrimer technology. Developed in 2013, Co-Diagnostics solely owned CoPrimer technology received its first patent from the United States Patent Office in 2018, and underpins the companys molecular diagnostic test products deployed in laboratories and hospitals in over 50 countries and across the US. 